Recurrent Ovarian Cancer Clinical Trial
Official title:
A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers
The main purpose of this study is to: - Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus - The study will also look at the levels of REGN4018 and/or cemiplimab in your body and measure how well your body can remove the study drug(s). This is called pharmacokinetics - The study will also look at any signs that REGN4018 alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus - To find out how safe and tolerable the sarilumab pretreatment is, in combination with REGN4018 and cemiplimab
Status | Recruiting |
Enrollment | 690 |
Est. completion date | June 21, 2026 |
Est. primary completion date | June 21, 2026 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: 1. Ovarian Cancer Cohorts Only: Patients with histologically or cytologically confirmed diagnosis of advanced, epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer who have all of the following: 1. serum CA-125 level =2 x upper limit of normal (ULN) (in screening) 2. has received at least 1 line of platinum-containing therapy or must be platinum-intolerant (applicable for dose escalation and non-randomized dose expansion cohorts) 3. documented relapse or progression on or after the most recent line of therapy 4. no standard therapy options likely to convey clinical benefit 2. Adequate organ and bone marrow function as defined in the protocol 3. Life expectancy of at least 3 months 4. Randomized phase 2 expansion cohort (Ovarian Cancer only): Platinum-resistant ovarian cancer patients who have had 1 to 3 lines of platinum-based therapy as defined in the protocol. 5. Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-Programmed Cell Death Ligand 1 (PD-1) therapy and platinum-based chemotherapy: 1. MUC16 positivity of tumor cells =25% by immunohistochemistry (IHC) 2. 1-2 prior lines of systemic therapy Key Exclusion Criteria: 1. Prior treatment with anti-Programmed Cell Death (PD-1)/PD-L1 therapy, as described in the protocol 2. Ovarian Cancer Expansion cohorts only: More than 4 prior lines of cytotoxic chemotherapy 3. Prior treatment with a MUC16 - targeted therapy 4. Untreated or active primary brain tumor, central nervous system (CNS) metastases, or spinal cord compression, as described in the protocol 5. History and/or current cardiovascular disease, as defined in the protocol 6. Severe and/or uncontrolled hypertension at screening. Patients taking anti-hypertensive medication must be on a stable anti-hypertensive regimen Note: Other protocol Inclusion/Exclusion Criteria apply |
Country | Name | City | State |
---|---|---|---|
Australia | Peter MacCallum Cancer Center | Melbourne | Victoria |
Australia | Prince of Wales Hospital | Randwick | New South Wales |
Belgium | Grand Hôpital de Charleroi | Charleroi | Hainaut |
Belgium | Universitair Ziekenhuis Antwerpen | Edegem | Antwerp |
Belgium | UZLeuven | Leuven | Vlaams Brabant |
France | Centre Regional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest - Institut Bergonie | Bordeaux | |
France | UNICANCER - Centre Francois Baclesse (CFB) | Caen cedex 5 | |
France | Centre Georges-Francois Leclerc | Dijon cedex | Bourgogne |
France | Centre Antoine Lacassagne | Nice | Cedex 2 |
France | Centre Hospitalier Lyon Sud, Hospices Civils de Lyon | Pierre-Benite | Lyon |
France | Institut Gustave Roussy | Villejuif Cedex | |
Israel | Rambam Health Care Campus RHCC - Rambam Medical Center | Haifa | |
Israel | The Chaim Sheba Medical Center | Tel Hashomer | |
Italy | Istituto Europeo di Oncologia | Milano | |
Italy | Instituto Nazionale Tumori- Fondazione Pascale | Naples | |
Italy | Fondazione Policlinico Agostino Gemelli IRCCS di Roma | Roma | Lazio |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Korea University Guro Hospital | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University College of Medicine | Seoul | |
Korea, Republic of | Yonsei University Health System | Seoul | |
Netherlands | University Medical Center Groningen | Groningen | |
Netherlands | Radboudumc, dept Medical Oncology hp 452 | Nijmegen | Gelderland |
Netherlands | Erasmus MC | Rotterdam | Zuid Holland |
Spain | Hospital Universitari Vall d'Hebron | Barcelona | |
Spain | Institut Catala d'Oncologia | Barcelona | |
Spain | Institut Catala d'Oncologia | Barcelona | |
Spain | Clinica Universidad de Navarra | Madrid | Navarre |
Spain | Hospital Universitario Fundacion Jimenez Diaz | Madrid | |
Spain | Hospital Universitario San Carlos | Madrid | |
Spain | Clínica Universidad de Navarra | Pamplona | Navarra |
Spain | Hospital Clinico Universitatio Santiago de Compostela | Santiago de Compostela | |
United Kingdom | Guy's Hospital | London | England |
United Kingdom | Imperial College Healthcare NHS Trust | London | |
United Kingdom | University College London Hospitals | London | England |
United Kingdom | The Christie NHS Foundation Trust | Manchester | Greater Manchester |
United Kingdom | University of Oxford | Oxford | Oxfordshire |
United Kingdom | Royal Marsden Hospital - Sutton | Sutton | Surrey |
United Kingdom | The Royal Marsden NHS Foundation Trust | Sutton | London |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | The General Hospital Corporation d/b/a Massachusetts General Hospital | Boston | Massachusetts |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | James Care Gynecologic Oncology at Mill Run | Hilliard | Ohio |
United States | Sarah Cannon Research Institute | Nashville | Tennessee |
United States | Columbia University Irving Medical Center | New York | New York |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Stephenson Cancer Center | Oklahoma City | Oklahoma |
United States | Virginia Commonwealth University Medical Center | Richmond | Virginia |
United States | Mayo Clinic Hospital Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Regeneron Pharmaceuticals |
United States, Australia, Belgium, France, Israel, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with Dose-limiting toxicity (DLTs) for REGN4018 monotherapy | Dose Escalation Phase | From Cycle 1, Day 1 up to 35 days | |
Primary | Number of participants with DLTs for REGN4018 with cemiplimab | Dose Escalation Phase | From Cycle 2, Day 1 up to 21 days | |
Primary | Number of participants with Treatment-emergent adverse event (TEAE)s (including immune-related adverse events (imAEs)) for REGN4018 monotherapy | Dose Escalation Phase | Up to 62 weeks | |
Primary | Number of participants with TEAEs (including imAEs) for REGN4018 with cemiplimab | Dose Escalation Phase | Up to 62 weeks | |
Primary | Number of participants with serious adverse events (SAEs) for REGN4018 monotherapy | Dose Escalation Phase | Up to 62 weeks | |
Primary | Number of participants with SAEs for REGN4018 with cemiplimab | Dose Escalation Phase | Up to 62 weeks | |
Primary | Number of deaths for REGN4018 monotherapy | Dose Escalation Phase | Up to 62 weeks | |
Primary | Number of deaths for REGN4018 with cemiplimab | Dose Escalation Phase | Up to 62 weeks | |
Primary | Number of participants with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) for REGN4018 monotherapy | Dose Escalation Phase | Up to 62 weeks | |
Primary | Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for REGN4018 with cemiplimab | Dose Escalation Phase | Up to 62 weeks | |
Primary | Concentration of REGN4018 in serum over time for REGN4018 monotherapy | Dose Escalation Phase | Up to 62 weeks | |
Primary | Concentration of REGN4018 in serum over time for REGN4018 with cemiplimab | Dose Escalation Phase | Up to 62 weeks | |
Primary | Objective response rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for REGN4018 monotherapy | Dose Expansion Phase | Up to 62 weeks | |
Primary | ORR defined by RECIST 1.1 for REGN4018 with cemiplimab | Dose Expansion Phase | Up to 62 weeks | |
Secondary | ORR based on RECIST 1.1 for REGN4018 monotherapy | Dose Escalation Phase | Up to 62 weeks | |
Secondary | ORR based on RECIST 1.1 for REGN4018 with cemiplimab | Dose Escalation Phase | Up to 62 weeks | |
Secondary | Number of participants with TEAEs (including imAEs) for REGN4018 monotherapy | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Number of participants with TEAEs (including imAEs) for REGN4018 with cemiplimab | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Number of participants with SAEs for REGN4018 monotherapy | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Number of participants with SAEs for REGN4018 with cemiplimab | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Number of deaths for REGN4018 monotherapy | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Number of deaths for REGN4018 with cemiplimab | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for REGN4018 monotherapy | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for REGN4018 with cemiplimab | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Concentration of REGN4018 in serum over time for REGN4018 monotherapy | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Concentration of REGN4018 in serum over time for REGN4018 with cemiplimab | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Change from baseline in quality of life (QoL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 GHS/QoL score for REGN4018 monotherapy | Dose Expansion Phase
The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social) , symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much." |
Baseline up to 62 weeks | |
Secondary | Change from baseline in quality of life (QoL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 GHS/QoL score for REGN4018 with cemiplimab | Dose Expansion Phase | Baseline up to 62 weeks | |
Secondary | Change from baseline in physical functioning as measured by the EORTC QLQ-C30 physical functioning score for REGN4018 monotherapy | Dose Expansion Phase | Baseline up to 62 weeks | |
Secondary | Change from baseline in physical functioning as measured by the EORTC QLQ-C30 physical functioning score for REGN4018 with cemiplimab | Dose Expansion Phase | Baseline up to 62 weeks | |
Secondary | Change from baseline in abdominal symptoms as measured by the Measure of Ovarian Symptoms and Treatment (MOST)-Abdominal index score for REGN4018 monotherapy | Dose Expansion Phase excluding the Endometrial Cancer Cohort
The MOST-24 is a 24-item questionnaire used to measure the impact of chemotherapy on symptoms (21 items) and well-being (3 items). The expected questionnaire completion time is less than 5 minutes. The prevalence of each MOST item at assessment time points can be summarized by providing the mean, standard deviation and proportions based on the MOST response format, a numeric rating scale with integers from zero to 10, with five verbal anchors: 'No trouble at all' (0), 'Mild' (1-3), 'Moderate' (4-6), 'Severe' (7-10), and 'Worst I can imagine' (10). |
Baseline up to 62 weeks | |
Secondary | Change from baseline in abdominal symptoms as measured by the MOST-Abdominal index score for REGN4018 with cemiplimab | Dose Expansion Phase Not applicable to Endometrial Cancer Cohort | Baseline up to 62 weeks | |
Secondary | Time to deterioration in GHS/QoL for REGN4018 monotherapy | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Time to deterioration in GHS/QoL for REGN4018 with cemiplimab | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Time to deterioration in physical functioning for REGN4018 monotherapy | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Time to deterioration in physical functioning for REGN4018 with cemiplimab | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Time to deterioration in abdominal symptoms for REGN4018 monotherapy | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Time to deterioration in abdominal symptoms for REGN4018 with cemiplimab | Dose Expansion Phase | Up to 62 weeks | |
Secondary | Change from baseline in QoL as measured by EQ-5D for REGN4018 monotherapy | Dose Expansion Phase | Baseline up to 62 weeks | |
Secondary | Change from baseline in QoL as measured by EQ-5D for REGN4018 with cemiplimab | Dose Expansion Phase | Baseline up to 62 weeks | |
Secondary | ORR based on iRECIST for REGN4018 monotherapy | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | ORR based on iRECIST for REGN4018 with cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | Best overall response (BOR) based on RECIST 1.1 for REGN4018 monotherapy | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | BOR based on iRECIST for REGN4018 monotherapy | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | BOR based on RECIST 1.1 for REGN4018 with cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | BOR based on iRECIST for REGN4018 with cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | Duration of response (DOR) based on RECIST 1.1 for REGN4018 monotherapy | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | DOR based on iRECIST for REGN4018 monotherapy | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | DOR based on RECIST 1.1 for REGN4018 with cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | DOR based on iRECIST for REGN4018 with cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | Disease control rate based on RECIST 1.1 for REGN4018 monotherapy | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | Disease control rate based on iRECIST for REGN4018 monotherapy | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | Disease control rate based on RECIST 1.1 for REGN4018 with cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | Disease control rate based on iRECIST for REGN4018 with cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | Complete response (CR) rate based on RECIST 1.1 for REGN4018 monotherapy | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | CR rate based on iRECIST 1.1 for REGN4018 monotherapy | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | CR rate based on RECIST 1.1 for REGN4018 with cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | CR rate based on iRECIST 1.1 for REGN4018 with cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | Progression-free survival (PFS) based on RECIST 1.1 for REGN4018 monotherapy | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | PFS based on iRECIST for REGN4018 monotherapy | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | PFS based on RECIST 1.1 for REGN4018 with cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | PFS based on iRECIST for REGN4018 with cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | Cancer antigen-125 (CA-125) response for REGN4018 monotherapy | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | CA-125 response for REGN4018 with cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | Presence or absence of anti-drug antibodies against REGN4018 | Dose Escalation and Dose Expansion Phases | Up to 62 weeks | |
Secondary | Presence or absence of anti-drug antibodies against cemiplimab | Dose Escalation and Dose Expansion Phases | Up to 62 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02195973 -
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05270720 -
Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06070285 -
Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
|
||
Completed |
NCT02303912 -
Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer
|
Phase 1 | |
Active, not recruiting |
NCT01802749 -
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
|
Phase 3 | |
Completed |
NCT02788708 -
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT05610735 -
Combination Therapy for Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02083536 -
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma
|
Phase 1 | |
Completed |
NCT03430518 -
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT03618706 -
Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT05311579 -
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01851746 -
A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
|
N/A | |
Active, not recruiting |
NCT06107868 -
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
|
Phase 1 | |
Recruiting |
NCT06308406 -
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06365853 -
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
|
Phase 2 | |
Completed |
NCT04718740 -
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05335993 -
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
|
Phase 2 | |
Completed |
NCT01381861 -
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05126342 -
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
|
Phase 2 | |
Completed |
NCT02849353 -
Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer
|
Phase 1/Phase 2 |